$AMPX
Amprius Technologies, Inc.

2022 Q1 Form 10-Q Financial Statement

#000119312522152074 Filed on May 17, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $2.110M $143.0K
YoY Change 1375.52%
Cost Of Revenue $3.149M $1.136M
YoY Change 177.2%
Gross Profit -$1.039M -$993.0K
YoY Change 4.63%
Gross Profit Margin -49.24% -694.41%
Selling, General & Admin $1.502M $521.0K
YoY Change 188.29%
% of Gross Profit
Research & Development $369.0K $346.0K
YoY Change 6.65%
% of Gross Profit
Depreciation & Amortization $334.0K $316.0K
YoY Change 5.7%
% of Gross Profit
Operating Expenses $1.871M $867.0K
YoY Change 115.8%
Operating Profit -$114.4K -$25.82K
YoY Change 343.05%
Interest Expense $0.00 -$2.000K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$141.4K -$7.000K
YoY Change 1920.44%
Pretax Income -$2.878M -$1.869M
YoY Change 53.99%
Income Tax
% Of Pretax Income
Net Earnings -$255.8K -$25.82K
YoY Change 890.76%
Net Earnings / Revenue -12.12% -18.06%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$34.19K -$22.21K
COMMON SHARES
Basic Shares Outstanding 65.77M shares
Diluted Shares Outstanding 65.77M shares

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.616M
YoY Change
Cash & Equivalents $2.651M
Short-Term Investments
Other Short-Term Assets $1.287M
YoY Change
Inventory $339.0K
Prepaid Expenses $350.0K
Receivables $471.0K $348.0K
Other Receivables $0.00
Total Short-Term Assets $3.001M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $6.866M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $89.00K
YoY Change
Total Long-Term Assets $230.0M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.001M
Total Long-Term Assets $230.0M
Total Assets $233.0M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $71.14K
YoY Change
Accrued Expenses $149.1K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $220.2K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $3.068M
YoY Change
Total Long-Term Liabilities $3.068M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $220.2K
Total Long-Term Liabilities $3.068M
Total Liabilities $24.07M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$21.04M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$21.04M -$822.00
YoY Change
Total Liabilities & Shareholders Equity $233.0M
YoY Change

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$255.8K -$25.82K
YoY Change 890.76%
Depreciation, Depletion And Amortization $334.0K $316.0K
YoY Change 5.7%
Cash From Operating Activities -$413.5K -$3.343M
YoY Change -87.63%
INVESTING ACTIVITIES
Capital Expenditures -$34.00K -$60.00K
YoY Change -43.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$230.0M -$60.00K
YoY Change 383233.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 233.0M 3.413M
YoY Change 6726.47%
NET CHANGE
Cash From Operating Activities -413.5K -3.343M
Cash From Investing Activities -230.0M -60.00K
Cash From Financing Activities 233.0M 3.413M
Net Change In Cash 2.574M 10.00K
YoY Change 25638.25%
FREE CASH FLOW
Cash From Operating Activities -$413.5K -$3.343M
Capital Expenditures -$34.00K -$60.00K
Free Cash Flow -$379.5K -$3.283M
YoY Change -88.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001899287
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
KENSINGTON CAPITAL ACQUISITION CORP. IV
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2022Q1 dei Entity File Number
EntityFileNumber
001-41314
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1591811
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1400 Old Country Road
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 301
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Westbury
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11590
CY2022Q1 dei City Area Code
CityAreaCode
703
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
674-6514
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
true
CY2022Q1 us-gaap Cash
Cash
2650976
CY2021Q4 us-gaap Cash
Cash
77151
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
350005
CY2022Q1 us-gaap Assets Current
AssetsCurrent
3000981
CY2021Q4 us-gaap Assets Current
AssetsCurrent
77151
CY2022Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
230032549
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
307243
CY2022Q1 us-gaap Assets
Assets
233033530
CY2021Q4 us-gaap Assets
Assets
384394
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
71138
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
63628
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
149103
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
155077
CY2021Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
200000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
220241
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
418705
CY2022Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
15600000
CY2022Q1 c0001899287 Deferred Underwriting Commissions Noncurrent
DeferredUnderwritingCommissionsNoncurrent
8050000
CY2022Q1 c0001899287 Working Capital Loan Related Party Noncurrent
WorkingCapitalLoanRelatedPartyNoncurrent
200000
CY2022Q1 us-gaap Liabilities
Liabilities
24070241
CY2021Q4 us-gaap Liabilities
Liabilities
418705
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
230000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
24014
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21037697
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59311
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-21036711
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-34311
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
233033530
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
384394
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
94404
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25822
CY2022Q1 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
20000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-114404
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25822
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-390000
CY2022Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
32549
CY2022Q1 c0001899287 Offering Costs Associated With Derivative Warrant Liabilities
OfferingCostsAssociatedWithDerivativeWarrantLiabilities
563980
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-141431
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-255835
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-25822
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-34311
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1440000
CY2022Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
22186565
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-255835
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-21036711
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
0
CY2021Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-25822
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-822
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-255835
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-25822
CY2021Q1 c0001899287 General And Administrative Expenses Paid By Related Party In Exchange For Issuance Of Class B Ordinary Shares
GeneralAndAdministrativeExpensesPaidByRelatedPartyInExchangeForIssuanceOfClassBOrdinaryShares
25000
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-390000
CY2022Q1 c0001899287 Offering Costs Associated With Derivative Warrant Liabilities
OfferingCostsAssociatedWithDerivativeWarrantLiabilities
563980
CY2022Q1 c0001899287 Income From Investments Held In Trust Account
IncomeFromInvestmentsHeldInTrustAccount
32549
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
350005
CY2022Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2573825
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77151
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2650976
CY2022Q1 c0001899287 Offering Costs Included In Accrued Expenses
OfferingCostsIncludedInAccruedExpenses
126000
CY2021Q1 c0001899287 Offering Costs Included In Accrued Expenses
OfferingCostsIncludedInAccruedExpenses
39266
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
57510
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6581
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
822
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-413480
CY2022Q1 us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
230000000
CY2022Q1 c0001899287 Deferred Underwriting Compensation
DeferredUnderwritingCompensation
8050000
CY2022Q1 c0001899287 Restricted Investments Term
RestrictedInvestmentsTerm
P185D
CY2022Q1 c0001899287 Percentage Of Public Shares To Be Redeemed On Non Completion Of Business Combination
PercentageOfPublicSharesToBeRedeemedOnNonCompletionOfBusinessCombination
1
CY2022Q1 c0001899287 Lock In Period For Redemption Of Public Shares After Closing Of Ipo
LockInPeriodForRedemptionOfPublicSharesAfterClosingOfIpo
P24M
CY2022Q1 c0001899287 Dissolution Expense
DissolutionExpense
100000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-230000000
CY2022Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
230000000
CY2022Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
8000000
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5012695
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
232987305
CY2022Q1 c0001899287 Minimum Share Price Of The Residual Assets Remaining Available For Distribution
MinimumSharePriceOfTheResidualAssetsRemainingAvailableForDistribution
10.00
CY2022Q1 us-gaap Cash
Cash
2700000
CY2022Q1 c0001899287 Working Capital Deficit
WorkingCapitalDeficit
2800000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div>
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk</div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. As of March 31, 2022 and December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div></div>
CY2022Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
0
CY2021Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
0
CY2022Q1 c0001899287 Underwriting Discount Paid Per Unit
UnderwritingDiscountPaidPerUnit
0.20
CY2022Q1 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
4600000
CY2022Q1 c0001899287 Deferred Underwriting Commission Per Unit
DeferredUnderwritingCommissionPerUnit
0.35
CY2022Q1 c0001899287 Deferred Underwriting Commissions Noncurrent
DeferredUnderwritingCommissionsNoncurrent
8100000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
1741
CY2021Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
0

Files In Submission

Name View Source Status
0001193125-22-152074-index-headers.html Edgar Link pending
0001193125-22-152074-index.html Edgar Link pending
0001193125-22-152074.txt Edgar Link pending
0001193125-22-152074-xbrl.zip Edgar Link pending
c0001899287-20220331.xsd Edgar Link pending
d241535d10q.htm Edgar Link pending
d241535dex311.htm Edgar Link pending
d241535dex312.htm Edgar Link pending
d241535dex321.htm Edgar Link pending
d241535dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
c0001899287-20220331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
c0001899287-20220331_lab.xml Edgar Link unprocessable
d241535d10q_htm.xml Edgar Link completed
c0001899287-20220331_pre.xml Edgar Link unprocessable
c0001899287-20220331_cal.xml Edgar Link unprocessable